-+ 0.00%
-+ 0.00%
-+ 0.00%

Singapore OK's Novo's Wegovy as Treatment for Progressive Fatty Liver Disease in Adults

MT Newswires·09/23/2026 01:25:55
Listen to the news
01:25 AM EDT, 09/23/2026 (MT Newswires) -- Novo Nordisk (NOVO-B.CO) secured approval from Singapore's Health Sciences Authority for Wegovy as a treatment for the progressive form of fatty liver disease in adults. The regulator approved the once-weekly injectable 2.4-milligram semaglutide for noncirrhotic metabolic dysfunction-associated steatohepatitis and moderate to advanced liver fibrosis in combination with a reduced-calorie diet and increased physical activity, according to a Wednesday release. The Danish drugmaker supported the application for the drug with results from the placebo-controlled phase 3 Essence trial.